Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
Authors:
Open Access
- 26 June 2011
- journal article
- clinical trial-report
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 68 (3) , 805-813
Abstract
Purpose Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat. Methods Patients received a single panobinostat oral dose on day 1, followed by 4 days wash-out period. On days 5–9, ketoconazole was administered. On day 8, a single panobinostat dose was co-administered with ketoconazole. Panobinostat was administered as single agent three times a week on day 15 and onward. Results In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C max and AUC of panobinostat, respectively. No substantial change in T max or half-life was observed. No difference in panobinostat-pharmacokinetics between patients carrying CYP3A5*1/*3 and CYP3A5*3/*3 alleles was observed. Most frequently reported adverse events were gastrointestinal related. Patients had asymptomatic hypophosphatemia (64%), and urine analysis suggested renal phosphate wasting. Conclusions Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.Keywords
This publication has 17 references indexed in Scilit:
- Clinical Toxicities of Histone Deacetylase InhibitorsPharmaceuticals, 2010
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaBritish Journal of Haematology, 2009
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 InductionDrug Metabolism and Disposition, 2008
- Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomasNature Clinical Practice Oncology, 2008
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and LymphomasClinical Cancer Research, 2008
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaThe Oncologist, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005